Zhifei Biological Approved to Begin Phase III Trial of TB Vaccine
Chongqing Zhifei Biological Product Co. has been granted SFDA approval to begin a Phase III trial of an existing product, Mycobacterium Vaccae for Injection (Vaccae), as a vaccine for tuberculosis, a currently unmet need. Vaccae is an immune system modulator that the company currently sells as an adjuvant to treat TB. More details.... Stock Symbol: (SHE: 300122) Share this with colleagues: // //  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here